MaxCyte outlines $17M-$19M annualized savings through restructuring while reiterating SPL revenue guidance
Source: SeekingAlpha
2025-11-12 19:12:32 ET
More on MaxCyte
- MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript
- MaxCyte announces 34% workforce reduction to cut costs
- Seeking Alpha’s Quant Rating on MaxCyte
- Historical earnings data for MaxCyte
- Financial information for MaxCyte
Read the full article on Seeking Alpha
For further details see:
MaxCyte outlines $17M–$19M annualized savings through restructuring while reiterating SPL revenue guidance
MaxCyte Inc.
NASDAQ: MXCT
MXCT Trading
5.77% G/L:
$1.10 Last:
1,382,133 Volume:
$1.04 Open:
MXCT Latest News
May 12, 2026 04:05:00 pm
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MXCT Stock Data
$82,138,988
103,153,769
1.05%
195
N/A
Biotechnology & Life Sciences
Healthcare
US
Rockville
